Pathogens and Immunity (Jan 2025)

The TB27 Transcriptomic Model for Predicting Mycobacterium tuberculosis Culture Conversion

  • Maja Reimann,
  • Korkut Avsar,
  • Andrew DiNardo,
  • Torsten Goldmann,
  • Gunar Günther,
  • Michael Hoelscher,
  • Elmira Ibraim,
  • Barbara Kalsdorf,
  • Stefan Kaufmann,
  • Niklas Köhler,
  • Anna Mandalakas,
  • Florian Maurer,
  • Marius Müller,
  • Dörte Nitschkowski,
  • Ioana Olaru,
  • Cristina Popa,
  • Andrea Rachow,
  • Thierry Rolling,
  • Helmut Salzer,
  • Patricia Sanchez-Carballo,
  • Maren Schuhmann,
  • Dagmar Schaub,
  • Victor Spinu,
  • Elena Terhalle,
  • Markus Unnewehr,
  • Nika Zielinski,
  • Jan Heyckendorf,
  • Christoph Lange

DOI
https://doi.org/10.20411/pai.v10i1.770
Journal volume & issue
Vol. 10, no. 1

Abstract

Read online

Rationale: Treatment monitoring of tuberculosis patients is complicated by a slow growth rate of Mycobacterium tuberculosis. Recently, host RNA signatures have been used to monitor the response to tuberculosis treatment. Objective: Identifying and validating a whole blood-based RNA signature model to predict microbiological treatment responses in patients on tuberculosis therapy. Methods: Using a multi-step machine learning algorithm to identify an RNA-based algorithm to predict the remaining time to culture conversion at flexible time points during anti-tuberculosis therapy. Results: The identification cohort included 149 patients split into a training and a test cohort, to develop a multistep algorithm consisting of 27 genes (TB27) for predicting the remaining time to culture conversion (TCC) at any given time. In the test dataset, predicted TCC and observed TCC achieved a correlation coefficient of r=0.98. An external validation cohort of 34 patients shows a correlation between predicted and observed days to TCC also of r=0.98. Conclusion: We identified and validated a whole blood-based RNA signature (TB27) that demonstrates an excellent agreement between predicted and observed times to M. tuberculosis culture conversion during tuberculosis therapy. TB27 is a potential useful biomarker for anti-tuberculosis drug development and for prediction of treatment responses in clinical practice.

Keywords